The investigators hypothesize that in patients with diabetes and acute myocardial infarction
(MI), Ang II type-1 receptor blockade (AT1RB) attenuates left ventricle (LV) remodeling to a
greater extent than angiotensin converting enzyme (ACE) inhibitor therapy and that the
addition of xanthine oxidase (XO) inhibitor, Allopurinol, results in further improvement in
LV remodeling and function in the follow-up phase after MI.